Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPrasugrel (Effient): Platelet activation and aggregation inhibitor approved to reduce the rate of thrombotic CV events in patients with ACS undergoing PCI
Formulary , 08/11/09
Prasugrel is a thienopyridine–class inhibitor of platelet activation and aggregation. This agent was approved on July 10, 2009, to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI), including patients with unstable angina (UA) or non–ST–elevation myocardial infarction (NSTEMI) and patients with ST–elevation myocardial infarction (STEMI) managed with primary or delayed PCI.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Non-adherence to statin therapy: a major challenge for preventive cardiology
Expert Opinion in Pharmacotherapy, 12/08/09
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management
Pharmacoepidemiology and Drug Safety, 12/08/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
Inflammatory breast cancer: what are the treatment options
Expert Opinion in Pharmacotherapy, 12/08/09
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Expert Opinion on Investigational Drugs, 12/08/09
Sponsor
Article Search
Sponsor